No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SCLX Scilex Holding
- 1.930
- +0.050+2.66%
Close Jul 2 16:00 ET
- 2.570
- +0.640+33.16%
Post 19:59 ET
349.70MMarket Cap-1484P/E (TTM)
2.099High1.890Low2.31MVolume1.960Open1.880Pre Close5.05MTurnover1.96%Turnover RatioLossP/E (Static)181.19MShares6.55052wk High-1.84P/B228.12MFloat Cap0.73252wk Low--Dividend TTM118.20MShs Float16.900Historical High--Div YieldTTM11.12%Amplitude0.732Historical Low2.183Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Scilex Holding-Unit Semnur, Denali Capital Acquisition Eye Potential Combination
Scilex Holding's subsidiary and Denali Capital Acquisition signed a letter of intent for a proposed business combination.
Scilex Holding Explores Strategic Options for Semnur Pharmaceuticals
Express News | Denali Capital Acquisition: Parties Anticipate Seeking Approval From SPAC's Shareholders in H2 2024
Express News | Denali Capital Acquisition Corp - Letter of Intent Contemplates Combined Company Being Led by Scilex and Semnur's Current Management Team.
Express News | Denali Capital Acquisition Corp - Scilex Is Expected to Be Majority Holder of Combined Company Following Completion of Proposed Business Combination.
Express News | Denali Capital Acquisition: Anticipated Proceeds From Deal Expected to Fund Semnur's Lead Program, SP-102
Comments
2
$Scilex Holding(SCLX.US$ $Denali Capital Acquisition Corp(DECA.US$ Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: Deca) Enter Into a Letter of Intent for a Proposed Business Combination! Transaction value upto 2 billion!
3
$Scilex Holding(SCLX.US$
Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)
▪️The Phase 3 study results are being published in PAIN® Journal, which is the leading journal devoted to pain medicine and research. PAIN is the official journal of the Internation...
Scilex Holding Company Announces Publication in PAIN Journal Regarding Phase 3 Results of the Pivotal Registration Trial of SP-102 (SEMDEXA™) in Lumbosacral Radicular Pain (Sciatica)
▪️The Phase 3 study results are being published in PAIN® Journal, which is the leading journal devoted to pain medicine and research. PAIN is the official journal of the Internation...
2
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg